54.39
                                            전일 마감가:
              $56.50
            열려 있는:
              $56.33
            하루 거래량:
                463.25K
            Relative Volume:
              0.56
            시가총액:
                $3.05B
            수익:
              $665.13M
            순이익/손실:
              $64.50M
            주가수익비율:
              47.54
            EPS:
                1.1442
            순현금흐름:
                $185.87M
            1주 성능:
              +3.33%
            1개월 성능:
              +14.22%
            6개월 성능:
                +68.06%
            1년 성능:
              +60.22%
            Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
명칭
                  
                      Supernus Pharmaceuticals Inc
                    
                전화
                  
                      301-838-2500
                    
                주소
                  
                      9715 KEY WEST AVENUE, ROCKVILLE, MD
                    
                SUPN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 | 
|---|---|---|---|---|---|---|
|   
                          
                                SUPN
                            
                             Supernus Pharmaceuticals Inc | 54.44 | 3.17B | 665.13M | 64.50M | 185.87M | 1.1442 | 
|   
                          
                                ZTS
                            
                             Zoetis Inc | 143.81 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 | 
|   
                          
                                TAK
                            
                             Takeda Pharmaceutical Co Adr | 13.36 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 | 
|   
                          
                                HLN
                            
                             Haleon Plc Adr | 9.245 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 | 
|   
                          
                                TEVA
                            
                             Teva Pharmaceutical Industries Ltd Adr | 20.15 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 | 
|   
                          
                                UTHR
                            
                             United Therapeutics Corp | 443.71 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 | 
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 | 
|---|---|---|---|
| 2025-10-09 | 업그레이드 | Piper Sandler | Neutral → Overweight | 
| 2025-07-30 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight | 
| 2025-02-19 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral | 
| 2025-01-06 | 개시 | Cantor Fitzgerald | Overweight | 
| 2024-09-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral | 
| 2023-01-03 | 재개 | Jefferies | Buy | 
| 2021-12-01 | 재개 | Jefferies | Buy | 
| 2021-04-13 | 업그레이드 | Jefferies | Hold → Buy | 
| 2020-06-16 | 업그레이드 | Piper Sandler | Neutral → Overweight | 
| 2020-06-15 | 재개 | Jefferies | Hold | 
| 2019-11-08 | 다운그레이드 | Berenberg | Buy → Hold | 
| 2019-11-07 | 다운그레이드 | Stifel | Buy → Hold | 
| 2019-11-06 | 다운그레이드 | Jefferies | Buy → Hold | 
| 2018-11-12 | 재확인 | B. Riley FBR | Buy | 
| 2018-01-18 | 재확인 | B. Riley FBR, Inc. | Buy | 
| 2017-12-28 | 재확인 | B. Riley FBR, Inc. | Buy | 
| 2017-12-04 | 업그레이드 | Janney | Neutral → Buy | 
| 2017-11-08 | 업그레이드 | Stifel | Hold → Buy | 
| 2017-10-19 | 개시 | FBR & Co. | Buy | 
| 2017-09-19 | 다운그레이드 | Stifel | Buy → Hold | 
| 2017-07-17 | 다운그레이드 | Piper Jaffray | Overweight → Neutral | 
| 2017-07-14 | 개시 | Janney | Neutral | 
| 2017-06-01 | 업그레이드 | Piper Jaffray | Neutral → Overweight | 
| 2016-07-18 | 다운그레이드 | Northland Capital | Outperform → Market Perform | 
| 2016-07-18 | 다운그레이드 | Piper Jaffray | Overweight → Neutral | 
| 2016-02-08 | 업그레이드 | Jefferies | Hold → Buy | 
| 2015-11-05 | 재확인 | Northland Capital | Outperform | 
| 2015-10-28 | 개시 | Northland Capital | Outperform | 
                    모두보기
                     
                  
                Supernus Pharmaceuticals Inc 주식(SUPN)의 최신 뉴스
Supernus a new buy at BofA on 'underappreciated' CNS assets - MSN
Can Supernus Pharmaceuticals Inc. stock continue upward trendPortfolio Performance Report & Long Hold Capital Preservation Plans - newser.com
Why Supernus Pharmaceuticals Inc. stock remains undervaluedBond Market & AI Forecasted Entry and Exit Points - newser.com
Supernus Pharmaceuticals Hits New 52-Week High of $55.95 - Markets Mojo
Supernus Pharmaceuticals Inc. stock trendline breakdownJuly 2025 Update & Consistent Profit Alerts - newser.com
How to monitor Supernus Pharmaceuticals Inc. with trend dashboardsJuly 2025 Price Swings & High Conviction Trade Alerts - newser.com
Long term hold vs stop loss in Supernus Pharmaceuticals Inc.IPO Watch & Risk Controlled Swing Alerts - newser.com
Top chart patterns to watch in Supernus Pharmaceuticals Inc.Watch List & Verified Short-Term Plans - newser.com
What institutional flow reveals about Supernus Pharmaceuticals Inc.Treasury Yields & Community Verified Trade Alerts - newser.com
Supernus Pharmaceuticals Inc Stock Analysis and ForecastQuarterly Earnings Review & Rapid Portfolio Appreciation - earlytimes.in
Supernus Pharmaceuticals (SUPN) Gains Market Attention with Key CNS Drugs - GuruFocus
Here's Why Supernus Pharmaceuticals (SUPN) is a Great Momentum Stock to Buy - sharewise.com
Can Supernus Pharmaceuticals Sustain Momentum After 13% Jump on Neuroscience Pipeline News? - Yahoo Finance
Supernus Pharmaceuticals Hits New 52-Week High of $53.28 - Markets Mojo
BofA Securities Initiates Supernus Pharmaceuticals at Buy With $65 Price Target - MarketScreener
B of A Securities Initiates Coverage on SUPN with a Buy Rating | - GuruFocus
Supernus Pharmaceuticals (SUPN) Price Target Increased by 32.88% to 59.36 - Nasdaq
B of A Securities Initiates Coverage of Supernus Pharmaceuticals (SUPN) with Buy Recommendation - Nasdaq
Is Supernus Pharmaceuticals Inc. stock near bottom after decline2025 Winners & Losers & Weekly Consistent Profit Watchlists - newser.com
Using data models to predict Supernus Pharmaceuticals Inc. stock movementTrade Analysis Summary & Safe Entry Trade Reports - newser.com
It’s Clear How Big Money Flows Lift Supernus - Yahoo Finance
Will Supernus Pharmaceuticals Inc. stock gain from lower inflationJuly 2025 Selloffs & Safe Entry Point Alerts - Fundação Cultural do Pará
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline - sharewise.com
Is Supernus Pharmaceuticals Inc. stock supported by strong fundamentalsWeekly Investment Summary & Smart Swing Trading Alerts - Fundação Cultural do Pará
Is Supernus Pharmaceuticals Inc. stock attractive after correctionEntry Point & Low Drawdown Trading Strategies - newser.com
Advanced analytics toolkit walkthrough for Supernus Pharmaceuticals Inc.2025 Year in Review & Daily Profit Maximizing Tips - newser.com
Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run? - sharewise.com
Sentiment analysis tools applied to Supernus Pharmaceuticals Inc.2025 Investor Takeaways & Risk Managed Trade Strategies - newser.com
How Supernus Pharmaceuticals Inc. stock reacts to Fed rate cutsTrade Volume Summary & Weekly Stock Breakout Alerts - newser.com
Supernus Pharmaceuticals Inc (SUPN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Supernus Pharmaceuticals Inc 주식 (SUPN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 | 
|---|---|---|---|---|---|---|---|
| Khattar Jack A. | President, CEO | Oct 09 '25 | Sale | 50.57 | 59,900 | 3,029,336 | 1,206,578 | 
| NEWHALL CHARLES W III | Director | Oct 09 '25 | Sale | 50.77 | 25,000 | 1,269,234 | 104,644 | 
                자본화:
                 
                  | 
                볼륨(24시간):
                 
            
         
                     
                             Stockscreener 앱 받기
                    Stockscreener 앱 받기